tiprankstipranks
Advertisement
Advertisement

APRE Stock Latest News

Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
RatingsAnalyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
7d ago
APRE
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
PremiumThe Fly
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
7d ago
APRE
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
PremiumThe Fly
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
9d ago
APRE
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
PremiumCompany Announcements
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
9d ago
8K
APRE
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
14d ago
ABX
CNH
Aprea Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyAprea Therapeutics initiated with an Outperform at Oppenheimer
15d ago
APRE
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
29d ago
APRE
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
Premium
Ratings
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
1M ago
APRE
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
PremiumCompany Announcements
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
2M ago
8K
APRE
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
PremiumThe Fly
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
2M ago
APRE
Aprea Therapeutics Announces $30 Million Private Placement
PremiumCompany Announcements
Aprea Therapeutics Announces $30 Million Private Placement
2M ago
8K
APRE
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
PremiumThe Fly
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
2M ago
APRE
Aprea Highlights Early APR-1051 Data and Financial Update
PremiumCompany AnnouncementsAprea Highlights Early APR-1051 Data and Financial Update
2M ago
8K
APRE
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
Premium
The Fly
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
2M ago
APRE
Aprea Therapeutics sees cash runway into 1Q27
Premium
The Fly
Aprea Therapeutics sees cash runway into 1Q27
2M ago
APRE
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
PremiumThe Fly
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
3M ago
APRE
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
PremiumRatings
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
3M ago
APRE
Aprea Highlights Encouraging Phase 1 Data for APR-1051
PremiumCompany Announcements
Aprea Highlights Encouraging Phase 1 Data for APR-1051
3M ago
8K
APRE
Aprea Therapeutics announces additional clinical activity for APR-1051
PremiumThe Fly
Aprea Therapeutics announces additional clinical activity for APR-1051
3M ago
APRE
Aprea announces expansions of its global intellectual property estate
PremiumThe FlyAprea announces expansions of its global intellectual property estate
3M ago
APRE
APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
Premium
Ratings
APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
3M ago
APRE
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
Premium
The Fly
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
3M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >